Mechanism of azithromycin treatment on gingival overgrowth

Journal of Dental Research

Volumn 87, Issue 11, 2008, Pages 1075-1079

  Kim, J Y ^a   Park, S H ^a   Cho, K S ^a,b   Kim, H J ^a   Lee, C K ^a,c   Park, K K ^a,b,c   Choi, S H ^a,b   Chung, W Y ^a,b,c  

^a Research Institute for Periodontal Regeneration   (South Korea)

^b Oral Science Research Institute   (South Korea)

^c Yonsei University College of Dentistry   (South Korea)

Author keywords

Azithromycin; Cyclosporin A; Gingival overgrowth; Matrix metalloprotease 2

Indexed keywords

AZITHROMYCIN; COLLAGEN TYPE 1; CYCLOSPORIN; ENZYME ACTIVATOR; GELATINASE A; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL PROLIFERATION; CHEMICALLY INDUCED DISORDER; CHONDROGENESIS; DRUG EFFECT; ENZYMOLOGY; FEMALE; FIBROBLAST; GINGIVA OVERGROWTH; HUMAN; KIDNEY TRANSPLANTATION; MALE; METABOLISM; MIDDLE AGED;

ADULT; AZITHROMYCIN; CELL PROLIFERATION; CELLS, CULTURED; CHONDROGENESIS; COLLAGEN TYPE I; CYCLOSPORINE; ENZYME ACTIVATORS; FEMALE; FIBROBLASTS; GINGIVAL OVERGROWTH; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED;

EID: 58149229712     PISSN: 00220345     EISSN: None     Source Type: Journal    
DOI: 10.1177/154405910808701110     Document Type: Article

References (33)

1. Aimes RT, Quiglcy JP (1995). Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4-and 1/4-length fragments, J Biol Chem 270:5872-5876.
2. Aimetti M, Romano F, DeBernardi C (2005). Effectiveness of periodontal therapy on the severity of cyclosporin A-indueed gingival overgrowth. J Clin Periodont 32:846-850.
3. Bader G, Lejeune S, Messner M (1998). Reduction of cyclosporin-induced gingival overgrowth following a change to tacrolimus. A ease history involving a liver transplant patient J Periodontal 69:729-732; erratum in J Periodontal 69:1181, 1998.
4. Barlold PM (1989). Regulation of human gingival fibroblast growth and synthetic activity by cyclosporin-A in vitro. J Periodontal Res 24:314-321.
5. Bolzani G, Delia Coletta R, Martelli Junior H, de Almeida OP, Graner E (2000). Cyclosporin A inhibits production and activity of matrix metallproteinases by gingival fibroblasts. J Periodontal Res 35:51 -58.
6. Bonnaure-Mallet M, Tricot-Doleux S, Godeau GJ (1995). Changes in extracellular matrix macromolecules in human gingival after treatment with drugs inducing gingival overgrowth. Arch Oral Biol 40:393-400.
7. Citterio F, Di Pinto A, Borzi MT, Scata MC, Foco M, Pozzetto U, et al. (2001). Azithromycin treatment of gingival hyperplasia in kidney transplant recipients is effective and safe. Transplant Proc 33:2134-2135.
8. Cotrim P, de Andrade CR, Martelli-Junior H, Graner E, Sauk JJ, Coletta RD (2002). Expression of matrix metalloproleinases in cyelosporin-treatcd gingival fibroblasts is regulated by transforming growth factor (TGF)-betal autocrine stimulation. J Periodontal 73:1313-1322.
9. Deryugina EI, Bourdon MA, Reisfeld RA, Strongin A (1998). Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metafloproteinase-2. Cancer Res 58:3743-3750.
10. Emonard HP, Remade AG, Noel AC, Grimaud JA, Stetler-Stevenson WG, Foidart JM (1992). Tumor cell surface-associated binding site for the M(r) 72,000 type IV collagenase. Cancer Res 52:5845-5848.
11. Gagliano N, Moscheni C, Dellavia C, Torn C, Stabellini G, Ferrario VF, et al. (2004). Effect of cyclosporin A on human gingival fibroblast collagen turnover in relation to the development of gingival overgrowth: an in vitro study. Biomed Pharmacother 58:231-238.
12. Gomez E, Sanchez-Nunez M, Sanchez JE, Corte C, Aguado S, Portal C, et al. (1997). Treatment of eyelosporin-induced gingival hyperplasia with azithromycin. Nephrol Dial Transplant 12:2694-2697.
13. Hyland PL, fraynor PS, Myrillas TT, Marley JJ, Linden GJ, Winter P, et al. (2003). The effects of cyclosporin on the collagenolytic activity of gingival fibroblasts. J Periodontal 74:437-445.
14. James JA, Boomer S, Maxwell AP, Hull PS, Short CD, Campbell BA, et al. (2000). Reduction in gingival overgrowth associated with conversion from cyclosporin A to tacrolimus. J Clin Periodontal 27:144-148.
15. Kataoka M, Shimizu Y, Kunikiyo K, Asahara Y, Yamashiia K, Ninomiya M, et al. (2000). Cyclosporin A decreases the degradation of type I collagen in rat gingival overgrowth. J Cell Physiol 182:351-358.
16. Kato T, Okahashi N, Kawai S, Kato T, Inaba FI, Morisaki I, et al. (2005). Impaired degradation of matrix collagen in human gingival fibroblasts by the antiepilcptic drug phenytoin. J Periodontal 76:941 -950.
17. Kubota T, Matsuki Y, Nomura T, Hara K (1997). In situ hybridization study on tissue inhibitors of metalloproleinases (TIMPs) mRNA-expressing cells in human inflamed gingival tissue. J Periodontal Res 32:467-472.
18. Kwun WFI, Suh BY, Kwun K B (2003). Effect of azithromycin in the treartment of eyelosporin-induced gingival hyperplasia in renal transplant recipients. Transplant Proc 35:311-312.
19. Nares S, Ng MC, Dill RE, Park B, Cutler CW, laeopino AM (1996). Cyclosporin A upregulates platelet-derived growth factor B chain in human hyperplastic gingiva. J Periodontal 67:271-270.
20. Noh HS, Chung WY, Choi SH, Cho KS, Park KK (2003). The effect of azithromycin on the cyclosporin A-induced gingival fibroblast overgrowth. J Kor A cad Periodontal 33:643-649.
21. Paik JW, Kim CS, Cho KS, Chai JK, Kim CK, Choi SH (2004). Inhibition of cyclosporin A-induced gingival overgrowth by azithromycin through phagocytosis: an in vivo and in vitro study. J Periodontal 75:380-387.
22. Pemu HE, Pcmu LM, Huttunen KR, Nieminen PA, Knuuttila ML (1992). Gingival overgrowth among renal transplant recipients related to immunosuppressive medication and possible local background factors. J Periodontal 63:548-553.
23. Schincaglia GP, Fomiti F, Cavallini R, Piva R, Calura G, del Senno L ( 1992). Cyclosporin-A increases type I procollagen production and mRNA level in human gingival fibroblasts in vitro. J Oral Pathol Med 21:181 -185.
24. Seymour RA, Jacobs DJ (1992). Cyclosporin A and the gingival tissues. J Clin Periodontal 19:1 -11.
25. Seymour RA, Thomason JM, Ellis JS (1996). The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontal 23:165-175.
26. Silva HC, Coletta RD, Jorge J, Bolzani G, de Almeida OP, Graner E (2001). The effect of cyclosporin A on the activity of matrix metalloproteinase during the healing of rat molar extraction wounds. Arch Oral Biol 46:875-879.
27. Sugano N, Ito K, Murai S (1998). Cyclosporin A inhibits collagenase gene expression via AP-1 and JNK suppression in human gingival fibroblasts. J Periodontal Res 33:448-452.
28. Tokgoz B, Sari HI, Yildiz O, Asian S, Sipahioglu M, Okten T, et al. (2004). Effects of azithromycin on cyclosporin-induced gingival hyperplasia in renal transplant patients. Transplant Proc 36:2699-2702.
29. Tuter G, Serdar MA, Yalim M, Gurhan IS, Balos K (2002). Evaluation of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 levels in gingival fibroblasts of cyclosporin A-trealed patients. J Periodontal 73:1273-1278.
30. Tyldesley WR, Rotter E (1984). Gingival hyperplasia induced by cyclosporin A. Br Dent J 157:305-309.
31. Wysocki GP, Gretzinger HA, Laupacis A, Ulan RA, Stiller CR (1983). Fibrous hyperplasia of the gingiva: a side effect of cyclosporin A therapy. Oral Sur Oral Med Oral Pathol 55:274-278.
32. Yamada FI, Nishimura F, Naruishi K, Chou FIFI, Takashiba S, Albright GM, et al. (2000). Phenytoin and cyclosporin A suppress the expression of MMP-1, TIMP-1, and cathepsin L, but not cathepsin B in cultured gingival fibroblasts. J Periodontal 71 ;955-960.
33. Yamaguehi M, Naruishi K, Yamada-Naruishi H, Omori K, Nishimura F, Takashiba S (2004). Long-term cyclosporin A exposure suppresses eathepsin-B and -L activity in gingival fibroblasts. J Periodontal Res 39:320-326.